Bayer Stock Juggles Twin FDA Accelerations and a $7.25 Billion Legal Countdown

U.S. FDA fast-tracks Bayer's Asundexian and Kerendia; Q1 net profit doubles to €2.76B, but free cash flow turns negative due to legal payouts. Analysts bullish, legal risks loom.

The U.S. Food and Drug Administration has placed not one but two Bayer drug candidates on the fast track, handing the German conglomerate a rare double dose of pipeline momentum. The agency granted Priority Review to Asundexian, an oral Factor XIa inhibitor designed to prevent strokes with a lower bleeding risk than current standards, and to Kerendia (finerenone) for an expanded indication treating chronic kidney disease in Type 1 diabetes patients. The six-month review window for both applications brings the company closer to plugging the revenue gap left by Xarelto's patent expiry.

Japan’s health ministry has also accepted the Asundexian filing, while China’s NMPA separately cleared Kerendia for heart failure patients based on the FINEARTS-HF study showing a significant reduction in cardiovascular events. That geographic spread gives the pipeline candidates heft in three of the world's largest pharmaceutical markets.

The operational numbers support the narrative of a business on the mend. First-quarter revenue rose on a currency-adjusted basis by just over four percent to €13.41 billion, with the Crop Science division adding a nearly seven percent growth tailwind. Earnings before interest, taxes, depreciation and amortisation, adjusted for special items, climbed to €4.45 billion, and net profit doubled to €2.76 billion – a sharp improvement that caught market attention.

Yet the cash flow statement tells a harsher story. Free cash flow plunged to minus €2.3 billion, with roughly €2 billion of that going toward U.S. legal settlements in the first quarter alone. The burden of ongoing glyphosate-related litigation continues to weigh on investor sentiment, and Bayer is leaning on its DSO efficiency program to cut costs, speed up decisions and strengthen the balance sheet.

Analysts are taking note of the improving fundamentals. DZ Bank upgraded its rating on the stock from Hold to Buy and raised the price target to €51, citing the strong start to the year and easing legal provisions. UBS and Barclays also maintain positive stances, pushing the average target to €42.44. The shares closed at €39.16 on Thursday, having gained 3.82 percent over the previous week, though the year-to-date advance of roughly 60 percent has pushed the relative strength index to 70.3 – a level that signals the short-term rally is getting stretched.

The legal calendar now becomes the defining narrative for June. On June 4, the objection period expires for a proposed $7.25 billion class-action settlement; a green light would lead to final court approval on July 9. Simultaneously, the U.S. Supreme Court is expected to rule by the end of the month in the Durnell v. Monsanto case, a decision that could reshape the liability landscape. Any setback could quickly overwhelm the positive signals from the pipeline.

Investors will get more clarity on May 27 when management speaks at the Deutsche Bank European Champions Conference in Frankfurt, likely offering updates on debt reduction and the DSO program. Second-quarter results are due on August 4. Until then, Bayer is playing a high-stakes game of pipeline progress versus legal drag – and both sides are moving fast.